Document is current
Any future updates will be listed below
-
Authors
Shah, Ibrahim H.
Salo-Mullen, Erin E. https://orcid.org/0000-0002-9602-8264
Amoroso, Kimberly A.
Kelsen, David
Stadler, Zsofia K. https://orcid.org/0000-0002-6985-2864
Hamilton, Jada G. https://orcid.org/0000-0001-8377-4666
-
Funding
Funding for this research was provided by:
National Cancer Institute (NCI P30 CA008748, NCI P30 CA008748, NCI P30 CA008748, NCI P30 CA008748, NCI P30 CA008748, NCI P30 CA008748)
National Center for Advancing Translational Sciences (UL1-TR-002384)
American Cancer Society (MRSG-16-020-01-CPPB)
- License Information
-
More Information
Article History
Received: 9 May 2022
Accepted: 12 August 2022
First Online: 2 September 2022
Declarations
:
: This study involved human participants and was reviewed and approved by the Institutional Review Boards (IRB) of Memorial Sloan Kettering Cancer Center. Verbal informed consent was obtained from all study participants as required by the IRB.
: Not applicable.
: Z.K.S. reports that an immediate family member holds consulting/advisory roles in Ophthalmology with Allergan, Adverum, Genentech/Roche, Novartis, Optos, Regeneron, Regenexbio, Neurogene, Gyroscope. Other authors have no conflicts of interest.
